

Shared and Specific Susceptibility Loci for Schizophrenia and Bipolar Disorder

A Dense Genome Scan in Eastern Quebec Families

Maziade et al., Molecular Psychiatry (2005)

Samantha Xinwei Han, Yongyan Liu

Part I: Background & Study Pedigrees

Study Objective

Primary Goal: Identify shared and disorder-specific susceptibility loci for schizophrenia (SZ) and bipolar disorder (BP)

Key Questions:

- Do SZ and BP **share** common genetic susceptibility loci?
- Are there loci **specific** to each disorder?

Why study SZ and BP together?

- Family studies show co-aggregation of SZ and BP within pedigrees
- Previous linkage studies analyzed the disorders separately
- Separate analysis may cause diagnostic misclassification to break segregation patterns within pedigrees

Background: The Diseases

Bipolar I Disorder (BP):

- Mood disorder with manic and depressive episodes
- Lifetime prevalence of 0.6%; Bipolar spectrum disorders: 1-2%
- **Highly heritable (60-85%)**
- ~70% reported psychotic symptoms

Schizophrenia (SZ):

- Key features include hallucinations, delusions, disorganized speech, abnormal motor behavior, diminished emotional expression
- Lifetime prevalence in population is 0.3-0.7%
- **High heritability (70-80%)**
- **Schizoaffective Disorder:**
 - Schizophrenia with mood symptoms (mania and/or depression)
 - lifetime prevalence is ~0.3%

Complex Disorders

- Non-Mendelian inheritance with incomplete penetrance
 - Carrying a susceptibility allele does not guarantee disease expression
- Genetic heterogeneity
 - Similar clinical phenotypes may result from different susceptibility loci or mutations across families
- Phenocopies
 - Similar clinical phenotype induced by environmental factors
 - Eg., prenatal or perinatal adversities including stress, infection, or other medical complications
- Other risk factors: neurodevelopmental factors, substance exposure, psychosocial stressors, etc.

Study Population: Eastern Quebec Families

Sample Characteristics:

- 21 multigenerational families from Eastern Quebec, Canada
- Average of 6 affected individuals (SZ or BP) per family
- N = 480 family members (DNA available)
- 47 deceased affected ancestors included in pedigree analysis

Family Selection Criteria:

- At least one first-degree relative with same disorder as proband
- At least two additional affected relatives (first/second/third-degree)
- At least four affected members per family

Family Composition:

- 7 SZ pedigrees (85%+ affected by SZ spectrum among ill members)
- 6 BP pedigrees (85%+ affected by BP spectrum among ill members)
- 8 mixed pedigrees (both SZ and BP)

Part II: Methods Overview

Methods: The Big Picture

Overall Analytical Strategy:

- Step 1: Define phenotypes (who is "affected"?)
- Step 2: Genotype families using microsatellite markers
- Step 3: Perform model-based linkage analysis
- Step 4: Calculate LOD scores across genome
- Step 5: Apply significance thresholds (multiple testing)
- Step 6: Identify candidate susceptibility regions

Background Concept: What is Linkage?

Linkage = The tendency for genes/markers close together on a chromosome to be inherited together

- Linkage analysis requires pedigree data because it detects co-segregation of chromosomal regions through meioses

Key Principle (from Lecture 4):

- If a marker is **physically close** to a disease gene, they will **co-segregate** within families
- The closer they are, the less likely recombination occurs between them

Recombination Fraction (θ):

- θ = probability of recombination between two loci
- $\theta = 0.5$: loci are unlinked (different chromosomes or far apart)
- $\theta < 0.5$: loci are linked
- $\theta = 0$: loci are completely linked (no recombination)

Background Concept: Microsatellite Markers

What are microsatellites?

- Short tandem repeats (STRs) of 2-4 nucleotides (e.g., CA-CA-CA-CA, or CA-CA, etc.)
- Highly polymorphic: many different alleles in population
- Scattered throughout the genome

Why use microsatellites for linkage analysis?

- High heterozygosity → more **informative meioses**
- A pedigree contributes to LOD score only if key individuals are heterozygous
- More alleles = better ability to track inheritance

This study used:

- 607 microsatellite markers
- 350 markers at 10cM resolution (initial scan)
- 257 additional markers in promising regions

Methods Step 1: Phenotype Definitions

Three diagnostic classes analyzed:

| Phenotype | Narrow Definition | Broad Definition |
|-----------|--|--|
| SZ | SZ only (N=71) | SZ+schizophreniform+schizotypal (N=81) |
| BP | BP I only (N=48) | BP I+BP II+recurrent depression (N=72) |
| CL | SZ + BP I + schizoaffective (N=134) | CL narrow+depression +schizotypal (N=169) |

CL = “Common Locus” phenotype

- Combines SZ and BP phenotypes
- Tests hypothesis that some loci are shared by both disorders

Diagnostic blindness: ensures that clinical diagnosis is assigned independently of family structure

Methods Step 2: Transmission Models

Model-based linkage analysis requires specifying:

- 1 **Mode of inheritance:** Dominant vs. Recessive
- 2 **Disease allele frequency:** How common is the risk allele?
- 3 **Penetrance:** $P(\text{affected} \mid \text{genotype})$

Two models used in this study:

| Parameter | Dominant Model | Recessive Model |
|--------------------------|----------------|-----------------|
| Disease allele frequency | 0.01 | 0.10 |
| Penetrance (high age) | 0.70 | 0.70 |
| Phenocopy rate | 0.20 | 0.10 |

Why test multiple models?

- True inheritance pattern is unknown for complex diseases
- Maximizing over models increases power but also Type I error

Background Concept: LOD Score

LOD (Log of Odds) Score measures evidence for linkage:

$$LOD(\theta) = \log_{10} \frac{L(\theta)}{L(\theta = 0.5)} = \log_{10} \frac{\text{Likelihood under linkage}}{\text{Likelihood under no linkage}}$$

When penetrance $f < 1$ or phenocopy rate $f_0 > 0$, the likelihood:

$$L(\theta) = \sum_{\text{genotypes}} P(\text{phenotypes} | \text{genotypes}, f, f_0) \cdot P(\text{genotypes} | \theta)$$

where for each individual i : $P(\text{phenotypes} | \text{genotypes}, f, f_0) = \prod_i P(Y_i | G_i)$

$$P(Y_i | G_i) = \begin{cases} f^{Y_i} (1 - f)^{1 - Y_i} & \text{if } G_i = \text{carrier} \\ f_0^{Y_i} (1 - f_0)^{1 - Y_i} & \text{if } G_i = \text{non-carrier} \end{cases}$$

Methods Step 3: Linkage Analysis Details

Two-point vs. Multipoint Analysis:

- **Two-point:** Tests linkage between disease and ONE marker
- **Three-point (multipoint):** Uses flanking markers together
 - More informative, extracts more information
 - Each marker included in two three-point analyses

Mod Score Approach:

- Maximize LOD score over θ AND over model parameters
-

$$\text{Mod Score} = \max_{\theta, \text{models}} \text{LOD}(\theta)$$

- Tests 8 combinations: 2 phenotype levels (narrow vs broad) \times 2 transmission models (dominant vs recessive) \times 2 analysis types (affect/unaffected vs affected-only)

Software: FASTLINK (version of LINKAGE)

Methods Step 4: Multiple Testing Correction

The Problem:

- 607 markers \times 3 phenotypes \times 8 model combinations = many tests!
- High risk of false positives

Solution: Lander & Kruglyak (1995) Thresholds

| Category | Z-score | Interpretation |
|---------------------|------------|---|
| Significant | ≥ 4.0 | Genomewide significant ($p < 0.05$) |
| Suggestive | ≥ 2.6 | Expected once per genome scan by chance |
| Confirmatory | ≥ 1.9 | Only in regions with prior evidence |

Additional correction in this study:

- Raised thresholds by 0.70 (following Hodge et al.)
- Because: 24 non-independent analyses per marker

Methods Step 5: Heterogeneity Analysis

What is genetic heterogeneity?

- Same phenotype caused by different genes in different families
- Common in complex diseases

Problem: If only some families are linked to a locus, the overall LOD score may be diluted

Solution: Admixture Model (HOMOG program)

- Estimates proportion of families linked (α)
- Calculates HLOD (heterogeneity LOD)
- Applied to signals with mod score > 1.9

$$HLOD = \log_{10} [\alpha \cdot L(\theta) + (1 - \alpha) \cdot L(\theta = 0.5)] - \log_{10} L(\theta = 0.5)$$

Part III: Results & Figures

Genetic Nomenclature: Loci and Markers

- **Chromosomal Location** (e.g., 15q11.1)
 - **15**: the chromosome number
 - **q**: the “long arm” of the chromosome (p stands for the “short arm”)
 - **11.1**: the specific band and sub-band on that arm, numbered in increasing order as the distance from the centromere (the center) increases
- **Genetic Markers** (e.g., D15S122)
 - **D**: DNA
 - **15**: located on Chromosome 15
 - **S**: a single-copy sequence (a unique genomic locus)
 - **122**: the unique ID number for this specific marker
- **The Relationship:**
 - **15q11.1** defines a broad chromosomal region
 - **D15S122** is a precise genetic marker within that region, used to test linkage to a nearby disease locus

Results (see Table 1)

- **Significant Linkage Findings** (MOD Score ≥ 4.0):
 - **BP**: 15q11.1 (D15S122), 18q12.3 (D18S1145), 16p12.3 (D16S410)
 - **CL**: 15q26 (D15S1014), 18q21.1 (D18S472)
- **Suggestive Linkage Findings** (MOD Score ≥ 2.6):
 - **BP**: 12q23.1 (D12S1030), 3q21.2 (D3S3023), 10p13 (D10S674)
 - **SZ**: 6p22.3 (D6S334), 18q21.1 (D18S851), 13q13.3 (D13S1491)
 - **CL**: 16p13.1 (D16S3041), 2q22.1 (D2S298), 13q14.1 (D13S1247)
- **Novelty and Replication** (see Table 3):
 - **Novel Discovery**: the linkage signal at **15q26** for the shared phenotype
 - **Confirmatory Evidence** (MOD score ≥ 1.9): the finding at **3q21.2** for BP, **6p22.3** for SZ, **10p15-p11** for BP and SZ, **18q12.3-q32** for BP and SZ, etc.

Table 2: Family Contributions to the Genetic Signal

- The linkage signal is supported by several pedigrees rather than driven by a single influential family


Table 2 Percentage of families according to their individual lod score contributing to the significant and suggestive total mod scores

| Marker | Mod score | Phenotype | Individual pedigree lod score interval | | | | | Highest family lod score |
|--------------------------------|-----------|-----------|--|-------------|-------------|-------------|---------|--------------------------|
| | | | lod<0.1 | 0.1≤lod<0.4 | 0.4≤lod<0.8 | 0.8≤lod<1.2 | 1.2≤lod | |
| Genomewide significant linkage | | | | | | | | |
| D15S122 | 4.59 | BP broad | 29% | 21% | 36% | 14% | 0% | 1.04 |
| D15S1014 | 4.55 | CL narrow | 29% | 48% | 19% | 0% | 5% | 1.22 |
| D16S410 | 4.05 | BP narrow | 21% | 21% | 57% | 0% | 0% | 0.61 |
| D16S3041 | 3.66 | CL broad | 33% | 29% | 38% | 0% | 0% | 0.67 |
| D18S1145 | 4.10 | BP broad | 43% | 21% | 21% | 7% | 7% | 1.21 |
| D18S472 | 4.46 | CL narrow | 33% | 43% | 24% | 0% | 0% | 0.71 |
| D18S851 | 3.87 | SZ narrow | 33% | 53% | 7% | 0% | 7% | 2.03 |
| Suggestive linkage | | | | | | | | |
| D2S298 | 2.76 | CL broad | 52% | 38% | 5% | 0% | 5% | 1.41 |
| D3S3023 | 2.68 | BP narrow | 57% | 14% | 21% | 7% | 0% | 1.04 |
| D6S334 | 2.82 | SZ narrow | 40% | 33% | 7% | 20% | 0% | 1.06 |
| D10S674 | 2.66 | BP narrow | 50% | 7% | 43% | 0% | 0% | 0.79 |
| D12S1030 | 3.53 | BP broad | 21% | 57% | 14% | 7% | 0% | 0.81 |
| D13S1491 | 2.96 | SZ narrow | 33% | 40% | 13% | 13% | 0% | 1.00 |
| D13S1247 | 2.74 | CL narrow | 57% | 19% | 14% | 5% | 5% | 1.69 |

For the analyses of the BP, the SZ and the CL phenotypes, the numbers of pedigrees under analysis were respectively 14, 15 and 21.

Figure 1: Visualizing Linkage across Chromosomes

- **X-axis:** physical distance along the chromosome (measured in cM)
- **Y-axis:** MOD score (the strength of the evidence)
- **Example:** Chromosome 18 shows overlapping linkage peaks for SZ, BP and the combined phenotype, suggesting a shared susceptibility locus rather than diagnosis-specific genes



Part IV: Discussion

Evidence for Shared Loci Between SZ and BP

- Data indicates overlapping susceptibility regions, suggesting that SZ and BP may share a common biological etiology in specific areas
- **Key Shared Hotspots:**
 - **Chromosome 18q:** showed consistent significant or suggestive linkage across SZ, BP, and combined phenotypes
 - **Chromosome 15q:** suggested the presence of one or more susceptibility genes contributing to either or both disorders
 - **Chromosome 16p:** primarily driven by BP and the shared phenotype, indicating a potential shared susceptibility locus; absence of a signal for SZ likely reflects diagnostic misclassification within pedigrees
- These results strongly support the hypothesis that some genetic risk factors are **not specific to one diagnosis** but are shared across the spectrum of these two major psychoses

Limitations

1. Statistical Thresholds

- Unclear if these criteria fit a small number of large families
- The effect of a two-step scan (sparse then dense) is hard to simulate

2. Sensitivity of Heterogeneity

- Current tests may fail to detect between-family heterogeneity

3. Complexity of Replication

- Difficult to define “true replication” across studies due to variations in:
 - Sampling & Diagnostics
 - Statistical methods & Genetic markers

Implications & Future Direction

- **Combination Model:** SZ and BP specificity arises from unique combinations of multiple shared genes
- **Modifier Gene Model:** SZ and BP share core genes, and specific modifier genes determine the final clinical phenotype
 - **Necessary but Not Sufficient:** Genes at loci like **6p22 (SZ)** or **16p12 (BP)** require interactions with other genes to trigger the disorder
 - **Affected-Only vs Affect/Unaffected:** More significant signals in AO analysis compared to AU
- **Future Directions**
 - The presence of multiple signals in one sample may allow for the study of gene-gene interactions (epistases)
 - Expand statistical power using a second sample of 500 members, ultimately identifying defective genes and paving the way for new treatments

Questions for Class Discussion

- 1 Why did the authors use **model-based** (parametric) linkage analysis instead of model-free methods for this study? What are the trade-offs?
- 2 The authors used both **narrow and broad** phenotype definitions. How might the phenotype definitions affect LOD scores and power?
- 3 We learned that LOD scores require specifying **penetrance** values. This study used age-dependent penetrance. Why is this important for late-onset disorders?
- 4 The maximum family LOD score was only ~ 2.0 (Table 2), yet the combined scores reached significance. What does this tell us about **genetic heterogeneity** of these disorders?
- 5 This is a **two-stage design** (initial sparse scan + dense follow-up). What are the advantages of this approach compared to performing dense genotyping from the start?